After years of manufacturing woes, Takeda is calling it quits on Natpara fkansteiner Tue, 10/04/2022 – 14:36 More: After years of manufacturing woes, Takeda is calling it quits on Natpara Source: fierce
read moreIn Daiichi case, court upholds jury’s $177.8M infringement ruling against Novartis zbecker Tue, 10/04/2022 – 11:18 More: In Daiichi case, court upholds jury's 7.8M infringement ruling against Novartis Source: fierce
read moreAstraZeneca’s Evusheld loses potency against new omicron subvariant, FDA warns kdunleavy Tue, 10/04/2022 – 10:37 More: AstraZeneca's Evusheld loses potency against new omicron subvariant, FDA warns Source: fierce
read morePfizer sees blockbuster potential for low-profile PARP drug Talzenna after prostate cancer combo win aliu Tue, 10/04/2022 – 10:03 More: Pfizer sees blockbuster potential for low-profile PARP drug Talzenna after prostate cancer combo win Source: fierce
read moreIn ‘skinny’ label fight between Teva and GSK, Supreme Court asks Biden admin for help fkansteiner Tue, 10/04/2022 – 09:35 More: In 'skinny' label fight between Teva and GSK, Supreme Court asks Biden admin for help Source: fierce
read moreTreatment involves adult patients with severe alopecia areata More: Eli Lilly receives marketing authorisation for baricitinib Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals